布地奈德联合肺表面活性物质对早产儿支气管肺发育不良的临床疗效

中国中西医结合儿科学 ›› 2021, Vol. 13 ›› Issue (4): 277-.

布地奈德联合肺表面活性物质对早产儿支气管肺发育不良的临床疗效

目的：探讨布地奈德联合肺表面活性物质（PS）预防早产儿支气管肺发育不良(BPD）的发生。
方法：选取2018年1月至2020年6月本院收治的呼吸窘迫综合征早产儿80例为研究对象，随机分为对照组和观察组各40例。对照组给予PS治疗，观察组给予布地奈德联合PS治疗。分析两组患儿治疗期间主要并发症、BPD发生率及严重程度、持续气道正压（CPAP）应用失败率、PS再次使用率等指标。
结果：观察组生后2、3、4 d氧合指数高于对照组，差异有统计学意义（P<0.05）。观察组患儿BPD发生率、PS再次使用率均低于对照组，差异有统计学意义（P<0.05）。两组CPAP治疗失败率和中-重度BPD发生率比较差异无统计学意义（P>0.05）。观察组呼吸支持使用时间、住院费用低于对照组，差异有统计学意义（P<0.05）;两组总住院时间比较差异无统计学意义(P>0.05)。两组治疗期间早产儿视网膜病、晚发型败血症、坏死性小肠结肠炎、动脉导管未闭发生率比较差异无统计学意义（P>0.05）。
结论:布地奈德联合PS治疗早产儿Ⅱ～Ⅲ级呼吸窘迫综合征，能改善早产儿肺功能，减少早产儿BPD的发生。

110032 沈阳，中国医科大学2018级临床药学专业本科生（李雯卉）；中国医科大学生命科学学院发育细胞生物学教研室（刘辉，李泽烨，韦佳祎，陈誉华）

出版日期:2021-08-25 发布日期:2021-12-07
通讯作者: 陈誉华，E-mail:yhchen@cmu.edu.cn
作者简介:李雯卉（2000-），女，中国医科大学2018级本科生在读。研究方向：临床药学
基金资助:
中国医科大学2019年大学生创新训练项目（201910159047）

Clinical effects of budesonide combined with pulmonary surfactant on bronchopulmonary dysplasia in preterm infants

Objective:To construct Atg7-gene-0knockout human brain microvascular endothelial cells(HBMEC) by CRISPR/cas9 technology, so as to provide an in vitro cell model for the role of Atg7 in the development of cerebral vessels, the mechanism of Atg7 participating in the formation of blood-brain barrier and thestudy of cerebrovascular diseases.#br# Methods:Two pairs of guiding RNA sequences(sgRNA) were designed according to exon 1 of human Atg7. HBMEC was transfected with lentivirus; puromycin and Pyricularia oryzae were used to screen for cells successfully transfected. RT-qPCR and Western blotting were used to detect the mRNA and protein of the target gene, and the morphological changes were observed under the microscope.#br# Results:The CRISPR/cas9 plasmid targeting Atg7 was constructed. The results of RT-qPCR, Western blot and immunofluorescence showed that stable Atg7-knockout human brain microvascular endothelial cell line was obtained by monoclonal screening. No obvious morphological changes were observed under light microscope.#br# Conclusion:The successful construction of human brain microvascular endothelial cells with Atg7 gene knockout by CRISPR/cas9 technology is beneficial to the development of cerebral vessels, the mechanism of blood-brain barrier morphogenesis and the study of cerebrovascular diseases.#br#

China Medical University, Shenyang 110032,China

Online:2021-08-25 Published:2021-12-07

摘要/Abstract

摘要： 目的：探讨布地奈德联合肺表面活性物质（PS）预防早产儿支气管肺发育不良(BPD）的发生。
方法：选取2018年1月至2020年6月本院收治的呼吸窘迫综合征早产儿80例为研究对象，随机分为对照组和观察组各40例。对照组给予PS治疗，观察组给予布地奈德联合PS治疗。分析两组患儿治疗期间主要并发症、BPD发生率及严重程度、持续气道正压（CPAP）应用失败率、PS再次使用率等指标。
结果：观察组生后2、3、4 d氧合指数高于对照组，差异有统计学意义（P<0.05）。观察组患儿BPD发生率、PS再次使用率均低于对照组，差异有统计学意义（P<0.05）。两组CPAP治疗失败率和中-重度BPD发生率比较差异无统计学意义（P>0.05）。观察组呼吸支持使用时间、住院费用低于对照组，差异有统计学意义（P<0.05）;两组总住院时间比较差异无统计学意义(P>0.05)。两组治疗期间早产儿视网膜病、晚发型败血症、坏死性小肠结肠炎、动脉导管未闭发生率比较差异无统计学意义（P>0.05）。
结论:布地奈德联合PS治疗早产儿Ⅱ～Ⅲ级呼吸窘迫综合征，能改善早产儿肺功能，减少早产儿BPD的发生。

关键词: 人脑微血管内皮细胞, Atg7基因, CRISPR/Cas9技术, 基因敲除

Abstract: Objective:To construct Atg7-gene-0knockout human brain microvascular endothelial cells(HBMEC) by CRISPR/cas9 technology, so as to provide an in vitro cell model for the role of Atg7 in the development of cerebral vessels, the mechanism of Atg7 participating in the formation of blood-brain barrier and thestudy of cerebrovascular diseases.
Methods:Two pairs of guiding RNA sequences(sgRNA) were designed according to exon 1 of human Atg7. HBMEC was transfected with lentivirus; puromycin and Pyricularia oryzae were used to screen for cells successfully transfected. RT-qPCR and Western blotting were used to detect the mRNA and protein of the target gene, and the morphological changes were observed under the microscope.
Results:The CRISPR/cas9 plasmid targeting Atg7 was constructed. The results of RT-qPCR, Western blot and immunofluorescence showed that stable Atg7-knockout human brain microvascular endothelial cell line was obtained by monoclonal screening. No obvious morphological changes were observed under light microscope.
Conclusion:The successful construction of human brain microvascular endothelial cells with Atg7 gene knockout by CRISPR/cas9 technology is beneficial to the development of cerebral vessels, the mechanism of blood-brain barrier morphogenesis and the study of cerebrovascular diseases.

Key words: HBMEC, Atg7 gene, CRISPR/cas9 technology, Gene knockout

朱曦怡, 温志红, 李福兵, 谢钰雁, 韦秀珍. 布地奈德联合肺表面活性物质对早产儿支气管肺发育不良的临床疗效[J]. 中国中西医结合儿科学, 2021, 13(4): 277-.

ZHU Xiyi, WEN Zhihong, LI Fubing, XIE Yuyan, WEI Xiuzhen. Clinical effects of budesonide combined with pulmonary surfactant on bronchopulmonary dysplasia in preterm infants[J]. Chinese Pediatrics of Integrated Traditional and Western Medicine, 2021, 13(4): 277-.